跨组织蛋白质组孟德尔随机化确定了血管痴呆症的治疗点
Cheng Wang1,2, Qiu-Han Xu1,3, Jun-Ming Zhu2
1School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Aging and disease
|November 10, 2025
概括
这项研究使用蛋白质门德尔随机化确定了与血管痴呆症 (VD) 相关的关键蛋白质. APOE是一个主要的驱动因素,潜在的药物点如 benserazide 已被确定为未来的治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 血管性痴呆 (VD) 是导致痴呆的主要原因,没有疾病修饰治疗.
- 大脑,脑液和血中的遗传相关蛋白质是有希望的治疗点.
- 缺乏针对静脉疾病相关蛋白质的全面的全蛋白质查.
研究的目的:
- 通过使用跨组织孟德尔随机化框架,对与静脉疾病相关的蛋白质进行全蛋白质查.
- 识别因果蛋白,探索代谢物介导作用,确定细胞类型特异性,并优先考虑治疗方法.
- 建立一个针对性治疗开发的框架在VD.
主要方法:
- 跨组织蛋白质组孟德尔随机化 (MR) 整合pQTL数据 (大脑,脑脊液,血) 与VD GWAS.
- 代谢体MR用于探索代谢物介导的效应.
- 单核RNA测序 (snRNA-seq) 用于细胞类型的特异性.
- 药物向相互作用分析和分子建模用于治疗优先级.
主要成果:
- APOE被确定为CSF和血中最强的VD相关蛋白质,表明系统相关性.
- 几个中枢神经系统特异性蛋白质 (14-3-3家族,AREG,SMOC1,UBE2G2) 完全与中枢神经有关.
- 代谢MR将特定代谢物与APOE和VD进展联系起来;在刺激神经元中观察到APOE上调.
- 班塞拉和普罗米辛被确定为最重要的候选药物.
结论:
- 系统地识别对VD进行基因验证的蛋白质基因标的系统识别.
- APOE已被确立为静脉疾病的中心分子驱动因素.
- 综合的框架结合多omics和药物发现支持精确医学的VD.
相关概念视频
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...